- Home
- Applications
- usa california
- tumor cells
Show results for
Refine by
Tumor Cells Product Applications In Usa California
8 applications found
In healthy individuals the vast majority of cfDNA derives from hematopoietic myeloid and lymph cells undergoing apoptosis. However, in individuals with cancer, a variable fraction of the cfDNA derives from tumor cells undergoing apoptosis and/or necrosis. This tumor derived fraction of cfDNA is known as circulating tumor DNA (ctDNA). The amount of ctDNA found in an individual with cancer depends on numerous parameters such as ...
ByClaret Bioscience based in Santa Cruz, CALIFORNIA (USA)
Use our platform to design antibodies that optimize binding affinity, titer, specific productivity, Immunogenicity, or other phenotypic variables of interest. Engineer antibodies that specifically kill cancer cells or equib cells with multiple functions, granting them the ability to invade human cancer-derived ...
ByTeselaGen Biotechnology, Inc. based in Portola Valley, CALIFORNIA (USA)
You need a complete answer to provide the best ...
ByBiocept based in San Diego, CALIFORNIA (USA)
High Performance Across the Breadth of Biotech. The NX One is a perfect fit for a wide variety of sectors and application areas spanning fundamental biological research to industrial and clinical workflows. Access your cells faster and at a fraction of the ...
ByNodexus Inc. based in Hayward, CALIFORNIA (USA)
Deliver the right cells to the patient on time. Maximize Functional Characterization of Your Precious T Cell Samples. The Opto™ Cell Therapy Development workflow accelerates the creation of better therapeutics by performing multiple functional assays across 1,000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link phenotype to gene ...
ByBruker Corporation based in Billerica, MASSACHUSETTS (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)
A liquid biopsy from Biocept gives you a new tool for profiling breast cancer—with a simple blood ...
ByBiocept based in San Diego, CALIFORNIA (USA)
Non-small cell lung cancer (NSCLC) is not a single disease, but a collection of cancer types whose pathology is classified by histology (cells) and molecular profiling (genetic and protein ...
ByBiocept based in San Diego, CALIFORNIA (USA)